TSS
DRUG

Two Sigma Securities’s Bright Minds Biosciences DRUG Stock Holding History

Two Sigma Securities’s Portfolio DRUG Stock Details DRUG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-3,345
Closed -$9.53K – 3044
2023
Q2 		$9.53K Buy
+3,345
New +$9.4K ﹤0.01% 2605
2022
Q4 		– Sell
-2,041
Closed -$13K – 2726
2022
Q3 		$13K Buy
+2,041
New +$13.2K ﹤0.01% 2355

Other funds holding DRUG

AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
APC
Aspire Private Capital Cornelius, North Carolina $484M AUM 17.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Two Sigma Securities's DRUG Position: Q3 2023 in Review

Two Sigma Securities sold out of Bright Minds Biosciences (DRUG) in Q3 2023, closing a stake of 3,345 shares — an estimated $9.53K sold.

Two Sigma Securities first reported a position in DRUG in Q3 2022 and held it in 2 quarters. The position peaked at $13K in Q3 2022. 6 funds tracked by Wall St. Rank hold DRUG as of Q3 2023.

  • Two Sigma Securities reported no remaining Bright Minds Biosciences position as of Q3 2023 after selling out during the quarter.
  • Two Sigma Securities sold 3,345 Bright Minds Biosciences shares in Q3 2023, an estimated $9.53K.
  • Two Sigma Securities first reported a position in Bright Minds Biosciences in Q3 2022 and held it in 2 quarters.
  • Two Sigma Securities's Bright Minds Biosciences position peaked at $13K in Q3 2022.
  • 6 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q3 2023.

Based on Two Sigma Securities's 13F filing for Q3 2023, filed 14 Nov 2023.